ADAR1 Capital Management’s Royalty Pharma RPRX Stock Holding History

ADAR1 Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$240K	Buy	+5,000	New	+$219K	0.01%	252
2025 Q1	–	Sell	-49,963	Closed	-$1.27M	–	245
2024 Q4	$1.27M	Sell	49,963 -1,046,703	-95%	-$27.8M	0.25%	69
2024 Q3	$31M	Sell	1,096,666 -84,666	-7%	-$2.35M	5.05%	7
2024 Q2	$31.2M	Buy	1,181,332 +460,031	+64%	+$12.8M	5.88%	6
2024 Q1	$21.9M	Sell	721,301 -600,533	-45%	-$17.7M	4.97%	9
2023 Q4	$37.1M	Buy	+1,321,834	New	+$36.3M	13.27%	2

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ADAR1 Capital Management's RPRX Position: Q1 2026 in Review

ADAR1 Capital Management opened a new position in Royalty Pharma (RPRX) in Q1 2026: 5,000 shares worth $240K. The stake represents 0.01% of the portfolio and ranks #252 among its holdings. This is a return to the name: ADAR1 Capital Management previously reported a position in RPRX as recently as Q4 2024.

ADAR1 Capital Management first reported a position in RPRX in Q4 2023 and has held it in 6 quarters since. The position peaked at $37.1M in Q4 2023. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

ADAR1 Capital Management held 5,000 shares of Royalty Pharma worth $240K as of Q1 2026.
Royalty Pharma was a new ADAR1 Capital Management position in Q1 2026.
Royalty Pharma made up 0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #252 holding.
ADAR1 Capital Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 6 quarters since.
ADAR1 Capital Management's Royalty Pharma position peaked at $37.1M in Q4 2023.
588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.